Stories from people navigating ESR1 mutation — diagnosis, treatment, caregiving, and the ordinary days in between.
3 stories
Oncology
The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy progression.
Rayan Salih · September 24, 2026 · 6 min
Women's Health
The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer that progressed after endocrine therapy.
Rayan Salih · 6 min read
Oncology
FDA approval makes vepdegestrant an option for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after prior endocrine therapy.
Dr. Abu Bakar · 6 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.